News

« Back to Recent News

Tradjenta (linagliptin) tablets and Jentadueto (linagliptin/metformin HCI) tablets: Focusing on What Matters, Improving Glycemic Control for Adult Patients With Type 2 Diabetes
Aug 27, 2013

Date & Time: August 27th, 2013 Tuesday, 6:30pm

Location: Sitar Indian Cuisine

Address: 420 Jordan Ln NW Huntsville, AL 35805 (256) 536-3360

Hosted By: Gary Otten, Boehringer-Ingelheim.and Shashi Kumr MD, aAPI

Message: Please register for this program today. 
  
3 WAYS TO REGISTER: 
  
1. RSVP thru the pingg e-mail you received. 
2. Contact Shashi Kumar at shashikumaram@yahoo.com 
3. Click the link below to register on our aAPI website. 
http://www.alabamaapi.org/calendar_detail.asp?id=5971  
 
Under the Physician Payment Sunshine Act Final Rule (Open Payments), beginning August 1, 2013 Pharma will be required to report all payments and transfers of value to physicians to the Centers for Medicare and Medicaid services (CMS). 
  
This program is open to healthcare practitioners (HCPs) for whom the information presented is relevant to their practice. Spouses or guests cannot be accommodated. By registering for this event I agree to allow Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), Lilly USA, LLC, and third parties associated with the execution of this program to contact me, by phone, fax, e-mail, or in person. BIPI and Lilly USA, LLC have adopted the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals that went into effect on July 1, 2002. Pursuant to the Code, inclusion of healthcare professionals’ spouses or guests is not permitted. We appreciate your understanding and support of our commitment to following TRADJENTA® (LINAGLIPTIN) TABLETS 
INDICATION AND IMPORTANT LIMITATIONS OF USE 
TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. 
IMPORTANT SAFETY INFORMATION 
CONTRAINDICATIONS 
TRADJENTA is contraindicated in patients with a history of hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. 
WARNINGS AND PRECAUTIONS 
Pancreatitis 
There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue TRADJENTA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA. 
  
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with TRADJENTA or any other antidiabetic drug.